AI Workbench

by Deep Genomics  · Based in Canada → — AI-Driven Discovery of Genetic Medicines
Neurology Oncology Pediatrics
Website
Claim this tool
Is this the maker? Claim the company →

Overview

Deep Genomics’ AI Workbench is an artificial intelligence-driven drug discovery platform focused on identifying and developing RNA-based therapies for genetic diseases.

The AI Workbench is primarily for researchers and pharmaceutical companies engaged in the preclinical discovery and development of genetic medicines. It is designed to accelerate the process of identifying therapeutic targets and designing oligonucleotide drug candidates. The platform has been applied to conditions such as Wilson disease, refractory gout, frontotemporal dementia, Niemann-Pick disease, pediatric epilepsy, and Parkinson’s disease.

In a research or drug development workflow, the AI Workbench integrates deep learning models with biological datasets to predict how genetic mutations cause disease at a molecular level. It then designs oligonucleotide therapies aimed at restoring normal cellular function by modulating RNA processing. This includes capabilities for analyzing vast genomic datasets, pinpointing underlying genetic mechanisms, and exploring billions of potential oligonucleotide sequences. The platform aims to reduce the time and cost associated with identifying drug candidates compared to traditional methods.

Notable capabilities include:

  • Target Identification: Algorithms scan thousands of diseases and mutations to identify precise disease-causing mechanisms.
  • Oligonucleotide Design: Tools explore numerous potential sequences to correct genetic defects.
  • BigRNA Foundation Model: An AI foundation model for RNA biology that predicts tissue-specific regulatory mechanisms of RNA expression and the effects of variants and candidate therapeutics.
  • Accelerated Discovery: Demonstrated ability to identify drug candidates in a shorter timeframe compared to traditional approaches.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven drug discovery platform (AI Workbench)
  • Biological Foundation Model (BioFM) Platform for scalable molecular design and target biology discovery
  • Decodes RNA biology to identify novel targets, mechanisms, and molecules
  • Predicts effects of genetic mutations and designs oligonucleotide therapies
  • Accelerates drug discovery timeline (e.g., 18 months from target identification to drug candidate for Wilson disease)
  • High preclinical success rates (e.g., 70% vs. pharma's 10-20%)
  • Lab-in-the-loop workflows for data generation and experimental validation
  • BigRNA foundation model for RNA biology, capable of analyzing 1 million DNA letters at base-resolution
  • Focus on steric blocking oligonucleotides (SBOs) for programmable therapies
  • Integrated AI into all business activities, from target identification to molecule design and safety assessment

Use Cases

  • Discovery and design of genetic medicines
  • Identification of novel targets for genetically defined diseases
  • Development of RNA-based drug candidates
  • Accelerating drug development for rare and complex genetic ailments
  • Treating metabolic disorders (e.g., Wilson disease, refractory gout)
  • Addressing neurological conditions (e.g., frontotemporal dementia, Parkinson's disease)

What Physicians Need to Know

Molecule Screening Capability
The AI Workbench is used to make billions of predictions across millions of genetic variants and test potentially billions of molecules. It designs oligonucleotide therapies and screens thousands of compounds to identify optimal candidates.
Clinical Trial Matching
While Deep Genomics focuses on drug discovery and development, other AI-powered solutions like DeepThink Health's Precision Trial Matching exist to help match patients to clinical trials based on their genetic and clinical profiles.
Real-World Evidence Analysis
The AI Workbench integrates vast datasets, including genomic, transcriptomic, and clinical data, to accelerate drug discovery and development.
Genomic Data Integration
The AI Workbench analyzes vast genomic datasets at an unprecedented scale to pinpoint underlying genetic mechanisms of disorders. It decodes the enormous complexity of RNA biology to find novel targets, mechanisms, and molecules. Deep Genomics also developed GenomeKit, a tool that streamlines the analysis of genomic sequences, annotations, and data tracks.
Literature Mining
The AI Workbench combines deep learning, automation, and advanced biomedical knowledge. While not explicitly stated as a direct feature of AI Workbench, the broader field of biomedical AI utilizes literature mining tools to navigate scientific databases and reveal connections between medications and health conditions.
Target Identification
The AI Workbench identifies novel genetic targets and predicts how specific RNA sequences can be modified to treat diseases. It scans thousands of diseases and hundreds of thousands of pathogenic mutations to identify precise disease-causing mechanisms. Deep Genomics is developing AI Workbench 3.0 to further refine target identification and expand the scope of treatable conditions, including more common and complex diseases involving multiple genes.
Safety Signal Detection
The AI Workbench enhances accuracy, ensuring that potential therapeutics are both effective and safe. Off-target prediction models assess genome-wide effects, eliminating toxic compounds before expensive synthesis.
Collaboration Features
Deep Genomics has engaged in collaborations, such as with BioMarin Pharmaceutical Inc., where the AI Workbench was used to identify and validate target mechanisms and lead candidates for rare disease indications. They also collaborate with institutions like Mila, the Quebec Artificial Intelligence Institute, to further develop AI applications for drug discovery.
Publication Support
Deep Genomics' work has led to groundbreaking papers, including one where their AI platform identified a novel treatment target and drug candidate for Wilson's disease. Publication and presentation of key outcomes are expected at future scientific meetings and journals.
Physician Tip

Physicians should be aware that Deep Genomics' AI Workbench is primarily a drug discovery and development platform focused on RNA-based therapeutics for genetically defined diseases. While it aims to accelerate the identification of effective and safe treatments, it is not a diagnostic tool for patients or for genetic counseling. The platform's capabilities in genomic data integration and target identification can lead to novel therapeutic candidates, particularly for rare and complex genetic conditions. For clinical trial matching, separate AI-powered solutions exist that leverage genomic and clinical data to identify suitable patients.

The Deep Genomics AI Workbench integrates deep learning, automation, advanced biomedical knowledge, and massive amounts of in vitro and in vivo data. It is complemented by tools like BigRNA for predicting RNA expression patterns and GenomeKit for streamlining genomic sequence analysis. The platform is designed to be a comprehensive suite of systems, with AI integrated into all business activities from target identification to molecule design and safety assessment.

Details

Category Drug Discovery & Research
Pricing Unknown — unknown
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Unknown AI-estimated

Deep Genomics is focused on drug discovery and development, with drug candidates in preclinical and early clinical stages. The company aims to advance programs into human testing.
Integrations
EHR Not specified
Specialties Neurology, Oncology, Pediatrics

What the Web Says

Deep Genomics' AI Workbench is a platform designed to accelerate the discovery and development of genetic therapies for diseases, particularly those without current cures. It leverages AI, machine learning, RNA biology, and automation to analyze vast genomic data, identify disease-causing mutations, and design oligonucleotide therapies. The platform has evolved through several versions, with AI Workbench 3.0 aiming to support drug discovery for more complex, multi-gene diseases.

Overall: Positive

Strengths

  • Accelerates drug discovery and development, reducing the time from target identification to drug candidate.
  • Identifies novel therapeutic targets and mechanisms for genetically defined diseases.
  • Enhances accuracy and reproducibility in predicting drug compound effectiveness.
  • Integrates advanced biological and medical knowledge with proprietary and public datasets.
  • Enables efficient searching of a vast oligonucleotide therapeutic design space.
  • Has achieved a 70% preclinical success rate, significantly higher than the traditional pharma rate of 10-20%.

Limitations

  • Currently focuses on central nervous system (CNS) and metabolic diseases, with research on other disease types in development.
  • Deep Genomics is not a genetic testing company and does not offer commercial tests, diagnoses, or genetic counseling to patients.
  • Limited public reviews from physicians, healthcare IT, or general tech reviewers outside of company-published or industry-focused articles.
  • Some AI workbenches, in general, have been noted to have issues with mobile optimization and can lead to higher costs for power users if not carefully monitored.
  • Challenges exist in integrating multimodal data (genomic sequences, imaging, clinical records) into unified and clinically robust pipelines for generative AI in medical genomics.

Based on reviews from: Deep Genomics review - 7 facts you should know [DECEMBER 2021], Deep Genomics u2013 Leveraging AI technology to rapidly discover and develop genetic therapies for unmet medical needs - CIO Bulletin, Deep Genomics: how the combination of precision medicine and AI is revolutionizing drug discovery | by Amplitude Ventures - Medium, Deep Genomics - Global Recognition Awards, Deep Genomics: AI-Driven RNA Therapeutics & Drug Discovery - CIO Bulletin, Deep Genomics Expands AI Platform for RNA Therapies - Drug Discovery and Development, Deep Genomics, now flush with cash, plans to take dozens of RNA therapies to the clinic, DeepBench Reviews 2026: Details, Pricing, & Features - G2, I built an AI workbench to free you from usage cap anxiety and enable quick model comparisons - Reddit, A systematic review on the generative AI applications in human medical genetics - PMC

Last updated: 2026-08-23

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AI Workbench

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Drug Discovery and Development
Deep Genomics Expands AI Platform for RNA Therapies
Deep Genomics has expanded its AI Workbench platform to target metabolic and neurological disorders, analyzing genomic data to identify therapeutic targets and design RNA-based drug candidates. The company is focusing on treatments for conditions like Wilson disease, refractory gout, and various neurological disorders.
2024-06
Deep Genomics Press Releases
Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics
Deep Genomics announced its AI foundation model, BigRNA, which utilizes DNA sequences to predict the effects of genetic variants on tissue-specific gene regulation, identify new RNA biology mechanisms, and design RNA therapeutic candidates. This proprietary platform, the AI Workbench, decodes RNA biology to find novel targets and molecules not accessible through traditional methods.
2023-09
CIO Bulletin
Deep Genomics: AI-Driven RNA Therapeutics & Drug Discovery - CIO Bulletin
Deep Genomics is leveraging its AI Workbench to navigate RNA biology, identify novel genetic targets, and predict how RNA sequences can be modified to treat diseases. The company is developing AI Workbench 3.0 to further refine target identification and expand the scope of treatable conditions.
unknown
Deep Genomics Press Releases
Deep Genomics Raises $180M in Series C Financing
Deep Genomics closed a $180 million Series C financing round to advance its AI-discovered programs towards the clinic, expand the AI Workbench, and scale its pipeline to 30 programs. The funding will support a large-scale data generation effort across 100 genes to identify novel targets and mechanisms.
2021-07
Medium (Amplitude Ventures)
Deep Genomics: how the combination of precision medicine and AI is revolutionizing drug discovery | by Amplitude Ventures
Deep Genomics' AI Workbench is a sophisticated system used to make billions of predictions across millions of genetic variants to test potential molecules. The company aims to expand its AI Workbench to address more complex and common diseases and rapidly scale its pipeline.
2021-07
Deep Genomics Press Releases
Mila Announces Collaboration with Leading AI Therapeutics Company Deep Genomics
Mila, the Quebec Artificial Intelligence Institute, announced a partnership with Deep Genomics, which will allow Deep Genomics to join Mila's community and leverage recruitment activities. Deep Genomics is expanding its AI Workbench and generating large-scale data to identify novel targets and advance programs into the clinic.
2021-09
PR Newswire
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
BioMarin Pharmaceutical Inc. and Deep Genomics entered a preclinical collaboration to use Deep Genomics' AI Workbench to identify oligonucleotide drug candidates for four rare disease indications. The AI Workbench combines deep learning, automation, and biomedical knowledge to identify targetable molecular mechanisms.
2020-11
Pharmaceutical Technology
BioMarin and Deep Genomics team up on AI rare disease drug discovery
Deep Genomics' AI Workbench, leveraging deep learning and extensive data, is central to its collaboration with BioMarin to discover oligonucleotide therapies for rare diseases. The second-generation Workbench enables the identification of genetic determinants of disease and lead therapeutic candidates.
2020-11

Videos

Product demos, reviews, and walkthroughs for AI Workbench.

View all on YouTube

Frequently Asked Questions

An AI Workbench, such as Anthropic's Claude Science, is an artificial intelligence platform designed to streamline scientific research, including drug discovery. For physicians involved in research, it can accelerate tasks like literature review, data analysis, and manuscript preparation. It can also help in identifying drug targets, designing molecules, and optimizing preclinical testing by analyzing large datasets and predicting drug-target interactions, pharmacokinetics, and toxicity.
AI Workbenches in drug discovery must ensure compliance by proving their systems are reliable, well-documented, and fit for purpose, while protecting data integrity and patient safety. This involves adherence to regulatory frameworks like Good Machine Learning Practice (GMLP), which requires detailed records of data sources, their provenance, quality, and potential biases. Documentation is crucial, including data provenance, version control, validation evidence, and governance procedures, to ensure traceability and reproducibility of scientific results.
Alternatives to a dedicated AI Workbench include various AI-powered drug discovery platforms that focus on different aspects of the research process. Some platforms specialize in target identification, molecular generation, biologics work, or predictive development layers. Examples include Recursion OS for end-to-end discovery, Insilico Pharma.AI for generative AI and small molecule design, Schru00f6dinger LiveDesign for physics-based AI, and others like AtomNet for small molecule screening.
While specific pricing for AI Workbenches like Claude Science isn't always publicly disclosed for individual users, other clinical AI tools and medical scribes offer various pricing models. Some AI scribe services can range from $19 to over $800 per provider per month, with options for free trials, usage-based pricing, tiered feature plans, or custom enterprise contracts. Institutional pricing for comprehensive drug discovery platforms is often negotiated based on volume, seat count, and integration scope.
Despite the advantages, AI Workbenches have limitations in drug discovery research. Key challenges include the need for vast amounts of high-quality, consistent, and unbiased data, as AI models rely heavily on this for effective functioning. The 'black-box' nature of some AI algorithms can also hinder understanding how decisions are made, posing a barrier to regulatory acceptance. Additionally, AI tools are not a substitute for human expertise and experimental methods; their predictions must be validated and interpreted by human researchers.
An AI Workbench like Claude Science is designed to integrate various tools and connectors into a single research environment, bringing together fragmented tools that scientists typically juggle. It can connect natively to numerous scientific databases and domain-specific open models, managing compute environments for users and saving a complete history of results for traceability. This allows for analysis of literature, execution of multi-step research, and iterative refinement of figures and manuscripts within one platform.
Yes, AI Workbenches and similar AI tools can contribute to personalized medicine in drug discovery. AI can help in designing individualized cancer vaccines by selecting neoantigens with the highest chance for success. By analyzing large datasets, AI can assist in predicting drug efficacy and toxicity, and optimizing molecular structures, which are crucial for developing more personalized treatments. This can lead to more targeted experiments and improved patient selection.

Related Tools

Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.
Free
Trially AI
Trially AI
Drug Discovery & Research
Trially's HIPAA-compliant AI platform matches, engages, and enrolls patients into trials with high accuracy, built for physicians and research sites.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.
Mendel.ai
Mendel.ai
Clinical Decision Support & Reference
Mendel.ai uses Neuro-Symbolic AI to sort patient cohorts from EHRs for clinical trial matching, accelerating research.
Contact for pricing
Haystack Enroll
Haystack Health
Drug Discovery & Research
Haystack Health is a clinical trial platform that utilizes AI and care navigation to connect health plan members and ACO patients with relevant clinical trials, aiming to expand treatment access and improve outcomes.
Custom quote
Dyania Health Clinical Trial Recruitment
Dyania Health
Drug Discovery & Research
Dyania Health's AI-powered software automates patient identification from EHRs for clinical trial recruitment, serving hospitals, health systems, and pharmaceutical companies.

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-08-23 | First Added: 2026-08-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.